
AKRO
Healthcare · Biotechnology · $4.50B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · -1.2% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 12, 2026 | Time not confirmed | -1.01 | 0.00 | +100.0% |
| Nov 7, 2025 | Time not confirmed | -0.93 | -0.99 | -6.2% |
| Aug 8, 2025 | Time not confirmed | -0.90 | -0.86 | +4.4% |
| May 8, 2025 | Before the open | -0.99 | -0.90 | +9.2% |
| Feb 26, 2025 | Before the open | -1.12 | -0.99 | +11.8% |
| Nov 11, 2024 | Before the open | -0.90 | -1.05 | -16.7% |
| Aug 9, 2024 | Before the open | -0.90 | -0.81 | +10.0% |
| May 10, 2024 | Before the open | -0.95 | -0.90 | +5.3% |
| Feb 29, 2024 | Before the open | -0.86 | -0.99 | -15.1% |
| Nov 13, 2023 | Before the open | -0.68 | -0.71 | -4.4% |
| Aug 11, 2023 | Before the open | -0.63 | -0.60 | +4.8% |
| May 15, 2023 | Before the open | -0.67 | -0.55 | +17.9% |
| Mar 17, 2023 | Before the open | -0.80 |
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic…
| -0.49 |
| +38.8% |
| Nov 4, 2022 | Before the open | -0.74 | -0.92 | -24.3% |
| Aug 4, 2022 | After the close | -0.86 | -0.77 | +10.5% |
| May 6, 2022 | Before the open | -0.80 | -0.74 | +7.5% |
| Feb 25, 2022 | Before the open | -0.82 | -0.93 | -13.4% |
| Nov 12, 2021 | Before the open | -0.91 | -0.70 | +23.1% |
| Aug 13, 2021 | Before the open | -0.72 | -0.83 | -15.3% |
| May 13, 2021 | Before the open | -0.91 | -0.43 | +52.7% |
| Mar 16, 2021 | Before the open | -0.59 | -0.86 | -45.8% |
| Nov 12, 2020 | After the close | -0.65 | -0.63 | +3.1% |
| Aug 12, 2020 | After the close | -0.62 | -0.57 | +8.1% |
| May 13, 2020 | After the close | -0.61 | -0.42 | +31.1% |
| Mar 16, 2020 | Before the open | -0.59 | -0.55 | +6.8% |
| Nov 12, 2019 | Before the open | -0.43 | -0.56 | -30.2% |
| Aug 12, 2019 | Before the open | -0.36 | -2.21 | -513.9% |
| Jun 20, 2019 | After the close | 0.00 | -0.23 | — |
| Jan 17, 2019 | Time not confirmed | — | -0.76 | — |